Were Analysts Bullish Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) This Week?

April 17, 2018 - By Adrian Erickson

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Logo

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ratings Coverage

Among 2 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galmed Pharmaceuticals Ltd had 3 analyst reports since November 15, 2017 according to SRatingsIntel. The rating was downgraded by Maxim Group on Wednesday, February 14 to “Hold”. Maxim Group upgraded the shares of GLMD in report on Thursday, March 15 to “Buy” rating. Below is a list of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) latest ratings and price target changes.

15/03/2018 Broker: Maxim Group Old Rating: Hold New Rating: Buy Upgrade
14/02/2018 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
15/11/2017 Broker: Roth Capital Rating: Buy New Target: $32 Initiates Coverage On

The stock increased 0.16% or $0.01 during the last trading session, reaching $6.16. About 1,626 shares traded. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 11.79% since April 17, 2017 and is uptrending. It has outperformed by 0.24% the S&P500.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company has market cap of $95.08 million. The firm is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It currently has negative earnings. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.